Skip to main content
You have permission to edit this article.
Edit
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

74.78 +0.25 (+0.34%)
Streaming Delayed Price Updated: 11:12 AM EDT, Aug 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,865,386
Open 74.36
Bid (Size) 74.78 (7)
Ask (Size) 74.79 (4)
Prev. Close 74.53
Today's Range 74.27 - 75.10
52wk Range 53.22 - 80.59
Shares Outstanding 2,222,113,553
Dividend Yield 2.62%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics
From Bristol Myers Squibb
Via Business Wire
Blue Chip Stocks In Focus: Bristol-Myers Squibb
The company has grown earnings by more than 20% per year on average over the last five and ten years. This explosive growth has enabled the company to continue growing its dividend. 
Via Talk Markets

Performance

YTD
+20.85%
+20.85%
1 Month
+1.42%
+1.42%
3 Month
-2.76%
-2.76%
6 Month
+11.94%
+11.94%
1 Year
+8.89%
+8.89%

More News

Read More
Why Michael Burry Is Betting Big on Just ONE Secretive Stock
Via InvestorPlace
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Bristol-Myers Squibb Expects Lower FY22 Sales Versus FY21
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Via Benzinga
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
Via Investor Brand Network
Exposures Product Safety
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
Via FinancialNewsMedia
Exposures Product Safety
2seventy Bio Shares Jump On Positive Data From Bristol Myers-Partnered Cancer Immunotherapy
Via Benzinga
Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
TC BioPharm Says It Aims To Deliver A Big Breakthrough In Cancer Treatments
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Looking At Bristol-Myers Squibb's Recent Whale Trades
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Bristol Myers Squibb to Host Virtual Investor Event to Discuss ESC 2022 Highlights
From Bristol Myers Squibb
Via Business Wire
Analyzing Bristol-Myers Squibb's Short Interest
Via Benzinga
Recap Of Friday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
Via Benzinga
Stock Market Rally Powers Higher On Fed Rate Hints; Apple, Microsoft, Meta, Amazon, Google Key Earnings: Weekly Review
Via Investor's Business Daily
Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
Aging Veterans May Have New Options As VA And Longeveron Make Progress On Clinical Research Of Aging Frailty Treatment
Via Benzinga
Bristol Myers Squibb Q2 Earnings And Revenues Surpass Estimates
Via Talk Markets
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Via Benzinga
The Generics Are Here: How Bristol Myers Squibb Expects Patent Losses To Hit In 2022
Via Investor's Business Daily
Recap: Bristol-Myers Squibb Q2 Earnings
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.